Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?
We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. The study did not meet its primary endpoint, with fasedienol failing to demonstrate a statistically meaningful improvement compared with place ...